ATE432925T1 - Neue imidazolcarboxamid-derivate als fructose-1,6-bisphosphatase-hemmer und pharmazeutische zusammensetzungen damit - Google Patents

Neue imidazolcarboxamid-derivate als fructose-1,6-bisphosphatase-hemmer und pharmazeutische zusammensetzungen damit

Info

Publication number
ATE432925T1
ATE432925T1 AT06776141T AT06776141T ATE432925T1 AT E432925 T1 ATE432925 T1 AT E432925T1 AT 06776141 T AT06776141 T AT 06776141T AT 06776141 T AT06776141 T AT 06776141T AT E432925 T1 ATE432925 T1 AT E432925T1
Authority
AT
Austria
Prior art keywords
fructose
pharmaceutical compositions
carboxamide derivatives
imidazole carboxamide
bisphosphatase inhibitors
Prior art date
Application number
AT06776141T
Other languages
English (en)
Inventor
Gerard Moinet
Gerard Botton
De Vacqueur Annick Arbellot
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE432925T1 publication Critical patent/ATE432925T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06776141T 2005-08-01 2006-07-07 Neue imidazolcarboxamid-derivate als fructose-1,6-bisphosphatase-hemmer und pharmazeutische zusammensetzungen damit ATE432925T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508211A FR2889190A1 (fr) 2005-08-01 2005-08-01 Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant
PCT/EP2006/006643 WO2007014619A1 (en) 2005-08-01 2006-07-07 Novelimidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same

Publications (1)

Publication Number Publication Date
ATE432925T1 true ATE432925T1 (de) 2009-06-15

Family

ID=36168401

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06776141T ATE432925T1 (de) 2005-08-01 2006-07-07 Neue imidazolcarboxamid-derivate als fructose-1,6-bisphosphatase-hemmer und pharmazeutische zusammensetzungen damit

Country Status (16)

Country Link
US (1) US8362057B2 (de)
EP (1) EP1910310B1 (de)
JP (1) JP5026421B2 (de)
KR (1) KR20080033489A (de)
CN (1) CN101233114A (de)
AR (1) AR055202A1 (de)
AT (1) ATE432925T1 (de)
AU (1) AU2006275172B2 (de)
BR (1) BRPI0614496A2 (de)
CA (1) CA2617282C (de)
DE (1) DE602006007148D1 (de)
ES (1) ES2326237T3 (de)
FR (1) FR2889190A1 (de)
MX (1) MX2008001489A (de)
WO (1) WO2007014619A1 (de)
ZA (1) ZA200801945B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2889190A1 (fr) 2005-08-01 2007-02-02 Merck Sante Soc Par Actions Si Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EP2102199B1 (de) * 2006-12-04 2011-04-27 AstraZeneca AB Antibakterielle polycyclische harnstoffverbindungen
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007047738A1 (de) * 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
WO2009058739A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Heterocyclic urea and thiourea derivatives and methods of use thereof
AU2008328956A1 (en) * 2007-11-30 2009-06-04 F. Hoffmann-La Roche Ag Pyridine compounds
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
SI2714668T1 (sl) * 2011-05-23 2017-06-30 Merck Patent Gmbh Tiazolni derivati
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9790188B2 (en) 2013-03-15 2017-10-17 Whitehead Institute For Biomedical Research Benzimidazole derivatives and uses thereof
EP4197596A1 (de) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Imidazolderivate zur behandlung und prophylaxe von infektionskrankheiten

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5628889A (en) * 1994-09-06 1997-05-13 International Business Machines Corporation High power capacity magnetron cathode
AU1811397A (en) * 1996-02-29 1997-09-16 Kissei Pharmaceutical Co. Ltd. Imidazole derivatives and vascular wall thickening inhibitor
JPH11147823A (ja) * 1997-11-17 1999-06-02 Kissei Pharmaceut Co Ltd 血管新生阻害剤
DE69910045T2 (de) * 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
AU2001232340A1 (en) 2000-02-18 2001-08-27 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
EP1752450A1 (de) * 2005-08-01 2007-02-14 Merck Sante Imidazolderivate als Fruktose-1,6-biphosphataseinhibitoren und pharmazeutische Zusammensetzungen diese enthaltend
FR2889190A1 (fr) 2005-08-01 2007-02-02 Merck Sante Soc Par Actions Si Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
WO2007014619A1 (en) 2007-02-08
EP1910310A1 (de) 2008-04-16
AU2006275172A1 (en) 2007-02-08
WO2007014619A8 (en) 2007-11-29
JP5026421B2 (ja) 2012-09-12
US20080207720A1 (en) 2008-08-28
KR20080033489A (ko) 2008-04-16
DE602006007148D1 (de) 2009-07-16
ES2326237T3 (es) 2009-10-05
AR055202A1 (es) 2007-08-08
JP2009502992A (ja) 2009-01-29
ZA200801945B (en) 2009-08-26
MX2008001489A (es) 2008-02-15
CA2617282A1 (en) 2007-02-08
FR2889190A1 (fr) 2007-02-02
CA2617282C (en) 2014-09-09
BRPI0614496A2 (pt) 2011-03-29
AU2006275172B2 (en) 2011-11-24
US8362057B2 (en) 2013-01-29
EP1910310B1 (de) 2009-06-03
CN101233114A (zh) 2008-07-30

Similar Documents

Publication Publication Date Title
ATE432925T1 (de) Neue imidazolcarboxamid-derivate als fructose-1,6-bisphosphatase-hemmer und pharmazeutische zusammensetzungen damit
ATE492545T1 (de) Verbindungen und zusammensetzungen als proteinkinase-hemmer
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
EP1871910A4 (de) Zusammensetzungen und verfahren zur verbesserung der wirkstoffempfindlichkeit und behandlung wirkstoffresistenter infektionen und krankheiten
DK1884242T3 (da) Farmaceutisk sammensætning omfattende lurasidon
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
ATE543825T1 (de) Spiro-oxindolverbindungen und ihre verwendungen als therapeutische mittel
DE602007014374D1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
ATE525374T1 (de) Heteroarylsubstituierte pyrroloä2,3-büpyridine und pyrroloä2,3-büpyrimidine als januskinaseinhibitoren
BRPI0511900A (pt) composições farmacêuticas
DK2783682T3 (da) Farmaceutisk sammensætning omfattende pimobendan
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE441639T1 (de) 2,4-diamino-pyrimidine als aurora inhibitoren
DE602005005456D1 (de) Neue azabicyclische derivate, herstellungsverfahren dafür und sie enthaltende pharmazeutische zusammensetzungen
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE453384T1 (de) Neue dosierformulierung
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
DK1939204T6 (da) Kondenseret heterocyklisk derivat, medicinalsammensætning indeholdende samme og medicinsk anvendelse deraf
DE602006018590D1 (de) Heteroarylharnstoffderivate zur hemmung von chk1
DK1587478T3 (da) Farmaceutisk sammensætning
ATE468338T1 (de) Pyrrolochinolinderivate und ihre verwendung als proteinkinasehemmer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties